🇺🇸 FDA
Patent

US 10568888

Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors

granted A61KA61K31/519A61P

Quick answer

US patent 10568888 (Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors) held by VTV THERAPEUTICS LLC expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
VTV THERAPEUTICS LLC
Grant date
Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/519, A61P, A61P1/00, A61P1/02